EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer

Nanoscale
Yuan LiZhengyu Jin

Abstract

Epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy. Herein, we report the synthesis of porphyrin-containing liposomal nanohybrid cerasomes decorated with cetuximab, an anti-EGFR antibody, and conjugated with IRDye800CW and MRI contrast DOTA-Gd, to enable in vivo tumor detection and photodynamic therapy (PDT). Moreover, PD-L1 was added for adjuvant therapy. The antitumor efficacy of PDT combined with PD-L1 immunotherapy was assessed. EGFR-targeted nanoparticles showed the targeted imaging of tumors. EGFR-targeted PDT combined with PD-L1 immunotherapy was more effective against tumor growth than simultaneous albeit nontargeted nanoparticle delivery with laser irradiation plus PD-L1 immunotherapy. Thus, EGFR-targeted nanoparticles exhibited significant potential toward dual-modality imaging-guided precise PDT, combined with immunotherapy.

References

Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Sep 29, 2006·European Journal of Radiology·Marie-France Bellin
Apr 23, 2010·Chemical Communications : Chem Comm·Zhong CaoJunichi Kikuchi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Dec 26, 2013·Advances in Colloid and Interface Science·Xiuli Yue, Zhifei Dai
Feb 8, 2014·Theranostics·Yan XingKai Chen
Mar 8, 2014·Pharmaceuticals·Wiebke SihverHans-Jürgen Pietzsch
Jun 25, 2015·BioMed Research International·Maria Gonzalez-Pons, Marcia Cruz-Correa
Aug 27, 2015·Bioconjugate Chemistry·Arutselvan NatarajanSanjiv S Gambhir
Sep 24, 2015·ACS Applied Materials & Interfaces·Lijia JingJie Tian
Nov 26, 2015·Journal of Immunology Research·Julie JacobsVanessa Deschoolmeester
May 31, 2016·Breast Care·Davide BedognettiBarbara Seliger
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naiyer A RizviScott Antonia
Oct 22, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S KandaT Tamura

❮ Previous
Next ❯

Citations

Jun 6, 2019·Chemical Society Reviews·Wei SangXiaoyuan Chen
Jul 30, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Lina WuXilin Sun
Oct 31, 2019·Journal of Oncology·Riccardo RampadoMarco Agostini
Dec 6, 2018·Pharmaceuticals·Tuanwei Li, Lifeng Yan
Aug 3, 2019·Acta Pharmacologica Sinica·Ang GaoHai-Jun Yu
Sep 30, 2019·Cellular and Molecular Life Sciences : CMLS·Mostafa Akbarzadeh KhiaviYadollah Omidi
Sep 12, 2019·Pathology Oncology Research : POR·Peipei YangJinzhou Feng
Dec 12, 2019·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Danushika C ManatungaK M Nalin de Silva
Jul 2, 2019·Seminars in Cancer Biology·Eluri PavitraYun Suk Huh
Feb 16, 2021·Frontiers in Chemistry·Amreen KhanRohit Srivastava
Mar 18, 2021·Journal of Liposome Research·Hanieh AbbasiSomayeh Handali
Apr 4, 2021·Acta Biomaterialia·Rui SangWei Deng
Jul 17, 2021·Global Challenges·Pantelitsa DimitriouDavid Barrow
Aug 25, 2021·ACS Biomaterials Science & Engineering·Kun LiYuanyu Huang
Sep 28, 2021·International Journal of Pharmaceutics·Phuoc Vinh NguyenEmilie Allard-Vannier

❮ Previous
Next ❯

Methods Mentioned

BETA
transmission
dynamic light scattering
fluorescence imaging

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.